A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm- producing methicillin-resistant staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2989-2992

  Barber, Katie E ^a   Werth, Brian J ^a   McRoberts, John P ^a   Rybaka, Michael J ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CEFTAROLINE; DAPTOMYCIN; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BIOFILM; BROTH DILUTION; CELL SURFACE; DRUG EXPOSURE; DRUG POTENTIATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; DRUG EFFECTS;

ANTI-BACTERIAL AGENTS; BIOFILMS; CEPHALOSPORINS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 84898603454     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02764-13     Document Type: Article

References (26)

1. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. 2013. Antimicrobialresistant pathogens associated with healthcare-Associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. Control Hosp. Epidemiol. 34:1-14. http://dx.doi.org/10.1086/668770.
2. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJA, Sherertz RJ, Warren DK. 2009. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49:1-45. http://dx.doi.org/10.1086/599376.
3. Lynch AS, Robertson GT. 2008. Bacterial and fungal biofilm infections. Annu. Rev. Med. 59:415-428. http://dx.doi.org/10.1146/annurev.med.59.110106. 132000.
4. Rosenthal VD, Maki DG, Salomao R, Moreno CA, Mehta Y, Higuera F, Cuellar LE, Arikan OA, Abouqal R, Leblebicioglu H, International Nosocomial Infection Control Consortium. 2006. Device-Associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann. Intern. Med. 145:582-591. http://dx.doi.org/10.7326/0003-4819-145-8-200610170-00007.
5. Khardori N, Yassien M. 1995. Biofilms in device-related infections. J. Ind. Microbiol. 15:141-147. http://dx.doi.org/10.1007/BF01569817.
6. Frank KL, Reichert EJ, Piper KE, Patel R. 2007. In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrob. Agents Chemother. 51:888-895. http://dx.doi.org/10.1128/AAC.01052-06.
7. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15:167-193. http://dx.doi.org/10.1128/CMR.15.2.167-193.2002.
8. Hall-Stoodley L, Costerton JW, Stoodley P. 2004. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2:95-108. http://dx.doi.org/10.1038/nrmicro821.
9. Patel R. 2005. Biofilms and antimicrobial resistance. Clin. Orthop. Relat. Res. 437:41-47. http://dx.doi.org/10.1097/01.blo.0000175714.68624.74.
10. Mah TF, O'Toole GA. 2001. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9:34-39. http://dx.doi.org/10.1016/ S0966-842X(00)01913-2.
11. Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG. 2008. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch. Intern. Med. 168:805-819. http://dx.doi.org/10. 1001/archinte.168.8.805.
12. Blaser J, Vergeres P, Widmer AF, Zimmerli W. 1995. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob. Agents Chemother. 39:1134-1139. http://dx.doi.org/10.1128/AAC.39.5. 1134.
13. Widmer AF, Frei R, Rajacic Z, Zimmerli W. 1990. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J. Infect. Dis. 162:96-102. http://dx.doi.org/10.1093/infdis/162.1. 96.
14. Werth BJ, Steed ME, Kaatz GW, Rybak MJ. 2013. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect." Antimicrob. Agents Chemother. 57:2664-2668. http://dx.doi.org/10. 1128/AAC.02308-12.
15. Vidaillac C, Leonard SN, Rybak MJ. 2009. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob. Agents Chemother. 53:4712-4717. http://dx.doi.org/10.1128/AAC.00636-09.
16. Gross M, Cramton SE, Gotz F, Peschel A. 2001. Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces. Infect. Immun. 69:3423-3426. http://dx.doi.org/10.1128/IAI.69.5.3423-3426.2001.
17. Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. 2013. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycinintermediate Staphylococcus aureus in a pharmacokinetic/ pharmacodynamic model. Antimicrob. Agents Chemother. 57:66-73. http://dx.doi.org/10.1128/AAC.01586-12.
18. Ceri H, Olson M, Morck D, Storey D, Read R, Buret A, Olson B. 2001. The MBEC assay system: multiple equivalent biofilms for antibiotic and biocide susceptibility testing. Methods Enzymol. 337:377-385. http://dx.doi.org/10.1016/ S0076-6879(01)37026-X.
19. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771-1776.
20. Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. 2000. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J. Microbiol. Methods 40:175-179. http://dx.doi.org/10.1016/S0167- 7012(00)00122-6.
21. Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF, Melton DM, Beachey EH. 1985. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J. Clin. Microbiol. 22:996-1006.
22. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. 2010. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob. Agents Chemother. 54:4329-4334. http://dx.doi.org/10.1128/ AAC.00455-10.
23. Straus SK, Hancock REW. 2006. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758:1215-1223. http://dx.doi.org/10.1016/j.bbamem.2006.02.009.
24. American Society for Microbiology. 8. Instructions to authors. Antimicrob. Agents Chemother. 52:1-23. http://dx.doi.org/10.1128/AAC.01407-07.
25. Beenken KE, Blevins JS, Smeltzer MS. 2003. Mutation of sarA in Staphylococcus aureus limits biofilm formation. Infect. Immun. 71:4206-4211. http://dx.doi.org/10.1128/IAI.71.7.4206-4211.2003.
26. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR, Infectious Diseases Society of America. 2013. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 56:e1-e25. http://dx.doi.org/10.1093/cid/cis803.